Quotient consolidates drug development business following three acquisitions

 

Newmarket, United Kingdom, May 19, 2008 – Quotient BioResearch Limited, the leading provider of analytical and safety evaluation services and products for bioscience and sport, announces that following the recent acquisitions of HFL Limited, GR Micro Limited and BioDynamics Research Limited, it is consolidating its drug development services businesses under the name Quotient Bioresearch and renaming the parent company of the Group Quotient Bioscience Limited (“Quotient Bioscience”).

 

Further Expansion for Quotient BioResearch in drug development services acquisition of BioDynamics 

 

Newmarket, United Kingdom, February 11, 2008 - Quotient BioResearch Limited ("Quotient BioResearch"), the leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired BioDynamics Research Limited ("BioDynamics").

 

FDA Clearance received by Alba Bioscience   

Edinburgh based Alba Bioscience has successfully received FDA clearance to manufacture 15 monoclonal blood typing reagents for supply into the US market. These ready-to-use reagents are critical for safe blood transfusion and include some unique products not previously available in the US.

It's a fresh start for the Alba Bioscience Team

Newmarket and Edinburgh, United Kingdom, August 31, 2007 – Quotient BioResearch Limited is pleased to announce that, together with management, it has acquired 100% of the business and assets of Alba Bioscience from the Scottish National Blood Transfusion Service. 

ISBT promotion

This new product consist of a panel of twelve anti-D's, specially selected for use in the identification of partial RhD types.

Diagnostic Scotland's New Identity

return to Media